These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1901335)

  • 1. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
    Antonelli G; Currenti M; Turriziani O; Dianzani F
    J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan.
    Hou C; Chuang WL; Yu ML; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY
    Scand J Gastroenterol; 2000 Dec; 35(12):1288-93. PubMed ID: 11199369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
    Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
    J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-interferon antibody in chronic hepatitis C].
    Arai K; Shindo M; Okuno T
    Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
    Hosoi H; Imai M; Yamanaka M
    J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.
    Giannelli G; Antonelli G; Fera G; Del Vecchio S; Riva E; Broccia C; Schiraldi O; Dianzani F
    Clin Exp Immunol; 1994 Jul; 97(1):4-9. PubMed ID: 8033418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
    Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
    Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
    Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
    Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
    J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
    Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
    J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha for viral hepatitis.
    Jonas MM
    J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):93-106. PubMed ID: 8856573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies.
    Prümmer O; Streichan U; Heimpel H; Porzsolt F
    J Immunol Methods; 1994 May; 171(1):45-53. PubMed ID: 8176238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.
    Ikeda Y; Toda G; Hashimoto N; Umeda N; Miyake K; Yamanaka M; Kurokowa K
    Clin Exp Immunol; 1991 Jul; 85(1):80-4. PubMed ID: 1906385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of interferon-alpha in virus infections.
    Finter NB; Chapman S; Dowd P; Johnston JM; Manna V; Sarantis N; Sheron N; Scott G; Phua S; Tatum PB
    Drugs; 1991 Nov; 42(5):749-65. PubMed ID: 1723372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy.
    Crowe JS; Gewert DR; Barber KA; Lewis AP; Sims MJ; Davies SL; Salom CL; Wood J; Thomas HC; Thursz M
    J Infect Dis; 1994 Apr; 169(4):875-8. PubMed ID: 8133104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.